SCHEMBL903215

SCHEMBL903215

CSc1nnc2ccccn12

nearest known ligand 0.54

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.54
RAB9A P51151 11/20 0.51
SMN1; SMN2 Q16637 9/20 0.51
KDM4E B2RXH2 5/20 0.51
NPC1 O15118 5/20 0.51
ALDH1A1 P00352 3/20 0.51
HPGD P15428 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11115568 0.80 RAB9A (0.51) LMNARAB9ASMN1; SMN2KDM4ENPC1
SCHEMBL12125640 0.79 LMNA (0.66) LMNARAB9ASMN1; SMN2KDM4ENPC1
SCHEMBL4870340 0.77 RAB9A (0.53) LMNARAB9ASMN1; SMN2KDM4ENPC1
SCHEMBL10571493 0.73 RAB9A (0.60) LMNARAB9ASMN1; SMN2KDM4ENPC1
SCHEMBL10575793 0.73 SMN1; SMN2 (0.60) LMNARAB9ASMN1; SMN2KDM4ENPC1
SCHEMBL1450345 0.72 KDM4E (0.55) LMNARAB9ASMN1; SMN2KDM4ENPC1
Hydrochloric Acid SCHEMBL10573853 0.72 KDM4E (0.53) LMNARAB9ASMN1; SMN2KDM4ENPC1
SCHEMBL1579458 0.72 LMNA (0.47) LMNARAB9ASMN1; SMN2KDM4ENPC1
SCHEMBL11188407 0.72 RAB9A (0.62) LMNARAB9ASMN1; SMN2KDM4ENPC1
SCHEMBL5818702 0.72 RAB9A (0.58) LMNARAB9ASMN1; SMN2KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3489232-A2 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) Syros Pharmaceuticals, Inc. (US) 2019-05-29 EP disclosed
US-8883828-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA INC. (US) 2014-11-11 US disclosed
US-20130065901-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2013-03-14 US disclosed
US-8354540-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA INC. (US) 2013-01-15 US disclosed
WO-2012044993-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING OR PREVENTING NEURODEGENERATIVE DISEASES OR DISORDERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2012-04-05 WO disclosed
US-20110281874-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2011-11-17 US disclosed
US-8022223-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090156603-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156603-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, PRKCSH LMNA 4096/4885RAB9A 3632/4885SMN1; SMN2 3368/4885
US-20130065901-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 LMNA 4132/4885RAB9A 2861/4885SMN1; SMN2 2184/4885
US-20110281874-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 LMNA 4132/4885RAB9A 2861/4885SMN1; SMN2 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.